Interpace Biosciences Interpace Biosciences Q1 Revenues Up 8 Percent The company attributed the revenue increase to improved performance in its clinical services business and increased reimbursement rates for its cancer tests. Interpace Biosciences to Review Strategic Alternatives The company, which was recently delisted from the Nasdaq, began a reorganization earlier this year in order to cut $7.2 million in annual costs. Interpace Biosciences Q4 Revenues More Than Double The company said that it is on track to meet its goal of shaving $7.2 million in costs this year as it undertakes a recently announced restructuring plan. Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing. Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management. Jan 20, 2021 Interpace Bio Q3 Revenues Rise 6 Percent Oct 20, 2020 Interpace Biosciences Q2 Revenues Decline 14 Percent Jun 26, 2020 Interpace Biosciences Q1 Revenues Rise 53 Percent Apr 23, 2020 Interpace Biosciences Q4 2019 Revenues Drop 29 Percent, Miss Analyst Predictions Jan 13, 2020 Interpace Biosciences to Sell $20M in Preferred Stock, Plans Reverse Stock Split Jan 6, 2020 Interpace Biosciences, University of North Carolina Launch Barrett's Esophagus Study Dec 20, 2019 Interpace Biosciences Expanding Beyond Dx, Cancer With Acquisition, Name Change Premium Nov 13, 2019 Interpace Diagnostics Reports 33 Percent Q3 Revenue Growth; Changes Name to Interpace Biosciences Oct 25, 2019 Cancer Genetics Settles Failed Merger Deal With NovellusDx; Receives $6M From Interpace Oct 17, 2019 Interpace Diagnostics Closes $13M Financing Investment Sep 30, 2019 Interpace Diagnostics Signs Thyroid Cancer Test Coverage Deals With Three BCBS Plans Sep 16, 2019 Interpace Diagnostics, Genecast Biotechnology Ink Worldwide Research Services Agreement Aug 13, 2019 Interpace Diagnostics Q2 Revenues Climb 14 Percent Jul 31, 2019 Interpace Diagnostics Thyroid Tests Covered In-Network by BCBS of Michigan Jul 29, 2019 Interpace Diagnostics Thyroid Assays Covered In-Network by Blue Shield of California Jul 22, 2019 Interpace Diagnostics, SelectHealth Sign Coverage Agreement for Thyroid Cancer Tests Jul 18, 2019 Helomics Inks Separate Pacts With UPMC, Interpace Dx for AI-Driven Oncology Decision Making Jul 15, 2019 Interpace Dx Acquires Cancer Genetics' Biopharma Services Jun 20, 2019 Interpace Diagnostics Thyroid Assays Covered by Independence Blue Cross May 13, 2019 Interpace Diagnostics Q1 Revenues Rise 25 Percent Load More Breaking News Sequencing Study Uncovers MERS-Related Coronavirus in Swiss Bats Angstrom Bio Raises $3M in Private Financing Eagle Biosciences, Genetic Analysis Ink Distribution Agreement for Gut Microbiota Test Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing Epizyme Partnering With Quest Diagnostics for Lymphoma Mutation Testing Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel The Scan CDC Calls Delta "Variant of Concern" CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern." From FDA to Venture Capital Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post. Consent Questions Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles. Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.